论文部分内容阅读
目的比较放化联合治疗与单纯化疗对局部晚期非小细胞肺癌(NSCLC)的临床疗效及安全性。方法 65例不能手术的NSCLC患者,分为单纯化疗组(A组)30例,放化疗联合组(B组)35例,A组给予紫杉醇联合顺铂方案化疗两周期,B组同A组并给予同步放疗方案。对比两组疗效及安全性。结果 A组治疗有效率、1年生存率分别为36.7%、30.0%;B组分别为65.7%、54.3%;B组较A组明显提高,差异有统计学意义(P=0.024,0.031)。患者治疗后主要不良反应为骨髓抑制及肝功能异常;A组白细胞减少、血小板减少和肝功能异常发生率分别为33.3%、3.3%和56.7%,B组则分别为36.6%、10.0%和60.0%,两组相比差异均无统计学意义(P=0.247,0.430,0.181)。结论对局部晚期NSCLC放化联合治疗优于单纯化疗,不良反应能耐受。
Objective To compare the clinical efficacy and safety of radiotherapy and chemotherapy combined with chemotherapy alone in the treatment of locally advanced non-small cell lung cancer (NSCLC). Methods Sixty-five patients with unresectable NSCLC were divided into chemotherapy group (A group), chemotherapy group (A group), radiotherapy and chemotherapy combination group (B group) 35 cases, A group received paclitaxel plus cisplatin regimen two cycles, B group with A group Give synchronous radiotherapy program. Compare the two groups efficacy and safety. Results The effective rate of treatment and the 1-year survival rate of group A were 36.7% and 30.0% respectively, while those of group B were 65.7% and 54.3% respectively. There was a significant difference between group B and group A (P = 0.024,0.031). The main adverse reactions after treatment were myelosuppression and abnormal liver function. The incidences of leukopenia, thrombocytopenia and abnormal liver function in group A were 33.3%, 3.3% and 56.7% respectively, while those in group B were 36.6%, 10.0% and 60.0% respectively %, No significant difference between the two groups (P = 0.247,0.430,0.181). Conclusion Radiotherapy combined with radiotherapy and chemotherapy for locally advanced NSCLC is better than chemotherapy alone. Adverse reactions can tolerate.